Aniket Bankar

List of Publications by Year
in descending order

11 papers	38 citations	1937685 4 h-index	1872680 6 g-index
11 all docs	11 docs citations	11 times ranked	82 citing authors

#	Article	IF	Citations
1	Investigational non-JAK inhibitors for chronic phase myelofibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 461-474.	4.1	13
2	Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leukemia and Lymphoma, 2020, 61, 1908-1919.	1.3	9
3	Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. British Journal of Haematology, 2021, 194, 557-567.	2.5	6
4	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. Transplantation and Cellular Therapy, 2021, 27, 600.e1-600.e8.	1.2	5
5	Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort. Leukemia, 2022, 36, 1689-1692.	7.2	4
6	5-Fluorotroxacitabine Displays Potent Anti-Leukemic Effects and Circumvents Resistance to Ara-C. Blood, 2018, 132, 3939-3939.	1.4	1
7	Tyrosine Kinase Inhibitors in the Clinical Setting: A Conundrum of Choices. Acta Haematologica, 2020, 143, 191-193.	1.4	0
8	Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study. Leukemia and Lymphoma, 2022, 63, 179-188.	1.3	0
9	Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia. Blood, 2018, 132, 3497-3497.	1.4	0
10	Factors Associated with Health Care Resource Utilization in Myeloproliferative Neoplasms: A Population-Based Cost Study. Blood, 2019, 134, 4169-4169.	1.4	0
11	Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy. Blood, 2020, 136, 22-22.	1.4	0